Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Program
On WRAL at 5: Non-profit employee arrested. What WRAL found about a local group meant to prevent violence and the now 5 people charged
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 07, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors
July 29, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
July 23, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
July 01, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
May 08, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
May 02, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
April 18, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
March 04, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
February 29, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
February 27, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Present at Upcoming Investor Conferences
February 22, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 21, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 08, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
December 05, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
December 04, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
November 29, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
November 27, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN
November 16, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 02, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting
November 01, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer
September 11, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 02, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
June 07, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces PDUFA Date Extension for Nirogacestat NDA
June 05, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors
May 30, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SWTX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.